Avalo Therapeutics (AVTX) Total Non-Current Liabilities (2015 - 2026)
Avalo Therapeutics posted quarterly Total Non-Current Liabilities of $31.6 million for Q1 2026, up 286.45% year-on-year from $8.2 million in Q1 2025, and up 104.85% on a QoQ basis from $15.4 million in Q4 2025.
Avalo Therapeutics (AVTX) has 12 years of Total Non-Current Liabilities data on file, last reported at $31.6 million in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities rose 286.45% year-over-year to $31.6 million; the trailing twelve-month figure through Mar 2026 stood at $31.6 million (up 286.45% YoY), and the FY2025 full-year result was $15.4 million, up 60.85% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $31.6 million, up from $15.4 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $223.5 million in Q1 2024 and bottomed at $8.2 million in Q1 2025.
- The 5-year median for Total Non-Current Liabilities is $33.4 million (2025), against an average of $45.0 million.
- The widest annual swing landed in 2024, when Total Non-Current Liabilities soared 564.01%; it then tumbled 96.35% in 2025.
- A 5-year view of Total Non-Current Liabilities shows it stood at $42.6 million in 2022, then sank by 71.05% to $12.3 million in 2023, then decreased by 22.26% to $9.6 million in 2024, then surged by 60.85% to $15.4 million in 2025, then surged by 104.85% to $31.6 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $31.6 million (Q1 2026), $15.4 million (Q4 2025), and $33.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Avalo Therapeutics | 317.29 Mn | 317.29 Mn | - | 31.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 31.57 Mn |
| Dec 31, 2025 | 15.41 Mn |
| Sep 30, 2025 | 33.44 Mn |
| Jun 30, 2025 | 11.75 Mn |
| Mar 31, 2025 | 8.17 Mn |
| Dec 31, 2024 | 9.58 Mn |
| Sep 30, 2024 | 63.91 Mn |
| Jun 30, 2024 | 109.28 Mn |
| Mar 31, 2024 | 223.53 Mn |
| Dec 31, 2023 | 12.32 Mn |
| Sep 30, 2023 | 9.63 Mn |
| Jun 30, 2023 | 26.15 Mn |
| Mar 31, 2023 | 40.87 Mn |
| Dec 31, 2022 | 42.57 Mn |
| Sep 30, 2022 | 36.78 Mn |
| Jun 30, 2022 | 36.24 Mn |
| Mar 31, 2022 | 53.20 Mn |
| Dec 31, 2021 | 54.83 Mn |
| Sep 30, 2021 | 53.65 Mn |
| Jun 30, 2021 | 40.94 Mn |
| Mar 31, 2021 | 28.47 Mn |
| Dec 31, 2020 | 17.32 Mn |
| Sep 30, 2020 | 18.69 Mn |
| Jun 30, 2020 | 16.60 Mn |
| Mar 31, 2020 | 17.44 Mn |
| Dec 31, 2019 | 14.00 Mn |
| Sep 30, 2019 | 37.85 Mn |
| Jun 30, 2019 | 40.71 Mn |
| Mar 31, 2019 | 44.95 Mn |
| Dec 31, 2018 | 48.96 Mn |
| Sep 30, 2018 | 40.55 Mn |
| Jun 30, 2018 | 34.70 Mn |
| Mar 31, 2018 | 40.47 Mn |
| Dec 31, 2017 | 14.92 Mn |
| Sep 30, 2017 | 4.83 Mn |
| Jun 30, 2017 | 1.66 Mn |
| Mar 31, 2017 | 2.74 Mn |
| Dec 31, 2016 | 5.56 Mn |
| Sep 30, 2016 | 7.50 Mn |
| Jun 30, 2016 | 7.20 Mn |
| Mar 31, 2016 | 7.66 Mn |
| Dec 31, 2015 | 8.20 Mn |
| Sep 30, 2015 | 9.85 Mn |